ABSTRACT
Coenzyme Q10 (ubiquinone or CoQ10) is a lipid molecule that acts as an electron mobile carrier of the electron transport chain and also contains antioxidant properties. Supplementation of CoQ10 has been very useful to treat mitochondrial diseases. CoQ10 along with its synthetic analogue, idebenone, is used largely to treat various neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, and Friedreich's ataxia and additional brain disease condition like autism, multiple sclerosis, epilepsy, depression, and bipolar disorder, which are related to mitochondrial impairment. In this article, we have reviewed numerous physiological functions of CoQ10 and the rationale for its use in clinical practice in different brain disorders.
Subject(s)
Brain Diseases/drug therapy , Mitochondrial Diseases/drug therapy , Ubiquinone/analogs & derivatives , Animals , Antioxidants/pharmacology , Brain Diseases/physiopathology , Humans , Mitochondria/drug effects , Mitochondria/pathology , Mitochondrial Diseases/physiopathology , Neurodegenerative Diseases/drug therapy , Neurodegenerative Diseases/physiopathology , Ubiquinone/pharmacologyABSTRACT
RATIONALE: Progressive encephalopathy with brain edema and/or leukoencephalopathy-1 is an infantile, lethal neurometabolic disorder caused by a NAD(P)HX epimerase (NAXE) gene mutation. It is characterized by a fluctuating disease course with repeated episodes of improvement and regression. In this report, we present a rare case of NAXE gene mutation-related encephalopathy with unexpected neurological recovery and long survival time. PATIENT CONCERNS: A 20-month-old girl presented with progressively unsteady gait and bilateral hand tremors after a trivial febrile illness. Her disease rapidly progressed to consciousness disturbance, 4-limb weakness (muscle power: 1/5 on the Medical Research Council scale), and respiratory failure. The patient gradually recovered 2âmonths later. However, another episode of severe fever-induced encephalopathy developed 2âyears after the initial presentation. DIAGNOSES: Results of laboratory investigations, including complete blood count, blood chemistry, inflammatory markers, and cerebral spinal fluid analysis were unremarkable. Electroencephalography and nerve conduction velocity studies yielded normal results. Brain magnetic resonance imaging on diffusion-weighted imaging revealed abnormal sysmmetric hyperintensity in the bilateral middle cerebellar peduncles. A genetic study using whole exome sequencing confirmed the diagnosis of NAXE gene mutation-related encephalopathy. INTERVENTIONS: Pulse therapy with methylprednisolone, intravenous immunoglobulin, coenzyme Q10, and carnitine were initially introduced. After a NAXE gene defect was detected, the vitamin B complex and coenzyme Q10 were administered. A continuous rehabilitation program was also implemented. OUTCOMES: NAXE gene mutation-related encephalopathy is usually regarded as a lethal neurometabolic disorder. However, the outcome in this case is better than that in the previous cases. She showed progressive neurological recovery and a longer survival time. The muscle power of the 4 limbs recovered to grade 4. At present (age of 5.5âyears old), she can walk with an unsteady gait and go to school. LESSONS: Although NAXE gene mutation-related encephalopathy is rare, it should be considered as a differential diagnosis of early onset progressive encephalopathy.
Subject(s)
Brain Diseases/genetics , Brain Diseases/physiopathology , Racemases and Epimerases/genetics , Dietary Supplements , Female , Humans , Infant , Ubiquinone/analogs & derivatives , Ubiquinone/therapeutic use , Vitamin B Complex/therapeutic use , Exome SequencingABSTRACT
Heart rate has natural fluctuations that are typically ascribed to autonomic function. Recent evidence suggests that conscious processing can affect the timing of the heartbeat. We hypothesized that heart rate is modulated by conscious processing and therefore dependent on attentional focus. To test this, we leverage the observation that neural processes synchronize between subjects by presenting an identical narrative stimulus. As predicted, we find significant inter-subject correlation of heart rate (ISC-HR) when subjects are presented with an auditory or audiovisual narrative. Consistent with our hypothesis, we find that ISC-HR is reduced when subjects are distracted from the narrative, and higher ISC-HR predicts better recall of the narrative. Finally, patients with disorders of consciousness have lower ISC-HR, as compared to healthy individuals. We conclude that heart rate fluctuations are partially driven by conscious processing, depend on attentional state, and may represent a simple metric to assess conscious state in unresponsive patients.
Subject(s)
Consciousness/physiology , Heart Rate/physiology , Acoustic Stimulation , Adolescent , Adult , Aged , Attention , Bayes Theorem , Brain Diseases/physiopathology , Cluster Analysis , Electrocardiography , Female , Humans , Male , Middle Aged , Photic Stimulation , Respiratory Rate , Young AdultABSTRACT
Gulf War Illness (GWI), a chronic multisymptom health problem, afflicts ~30% of veterans served in the first GW. Impaired brain function is among the most significant symptoms of GWI, which is typified by persistent cognitive and mood impairments, concentration problems, headaches, chronic fatigue, and musculoskeletal pain. This review aims to discuss findings from animal prototypes and veterans with GWI on mechanisms underlying its pathophysiology and emerging therapeutic strategies for alleviating brain dysfunction in GWI. Animal model studies have linked brain impairments to incessantly elevated oxidative stress, chronic inflammation, inhibitory interneuron loss, altered lipid metabolism and peroxisomes, mitochondrial dysfunction, modified expression of genes relevant to cognitive function, and waned hippocampal neurogenesis. Furthermore, the involvement of systemic alterations such as the increased intensity of reactive oxygen species and proinflammatory cytokines in the blood, transformed gut microbiome, and activation of the adaptive immune response have received consideration. Investigations in veterans have suggested that brain dysfunction in GWI is linked to chronic activation of the executive control network, impaired functional connectivity, altered blood flow, persistent inflammation, and changes in miRNA levels. Lack of protective alleles from Class II HLA genes, the altered concentration of phospholipid species and proinflammatory factors in the circulating blood have also been suggested as other aiding factors. While some drugs or combination therapies have shown promise for alleviating symptoms in clinical trials, larger double-blind, placebo-controlled trials are needed to validate such findings. Based on improvements seen in animal models of GWI, several antioxidants and anti-inflammatory compounds are currently being tested in clinical trials. However, reliable blood biomarkers that facilitate an appropriate screening of veterans for brain pathology need to be discovered. A liquid biopsy approach involving analysis of brain-derived extracellular vesicles in the blood appears efficient for discerning the extent of neuropathology both before and during clinical trials.
Subject(s)
Brain Diseases , Persian Gulf Syndrome , Animals , Brain Diseases/drug therapy , Brain Diseases/physiopathology , Gulf War , Humans , Inflammation , Neurogenesis , Persian Gulf Syndrome/drug therapy , Randomized Controlled Trials as TopicABSTRACT
OBJECTIVE: Encephalopathy with Status Epilepticus during slow Sleep (ESES) is a syndrome where neurocognitive impairment correlates with multifocal Electroencephalography (EEG) spikes increasing abruptly at sleep onset. Demonstration of a focal onset could provide important clues to unravel the mechanisms underlying the condition, but until know it has not been established. METHODS: We studied epileptic dynamics at sleep onset to assess its focal or diffuse features in five patients with perinatal thalamic hemorrhages lateralized to one hemisphere, using high resolution EEG. RESULTS: Dynamical functional connectivity revealed the information flow in the epileptic network and identified primary sources of outflow, equated with cortical spike sources. We found that spikes with important activation originate in restricted cortical areas of the hemisphere with the lesion, spreading widely and quickly at onset of N2 sleep stage. CONCLUSIONS: Perinatal thalamic lesions have the potential to induce, years later, a regional onset of epileptic activity with features of ESES in a cortex without apparent structural lesion. Most widespread spike activity in the scalp results from secondary propagation. SIGNIFICANCE: Perinatal thalamic lesions produce ESES with focal onset in a restricted cortical area of the hemisphere with the lesion, and prominent secondary propagation.
Subject(s)
Brain Diseases/physiopathology , Sleep/physiology , Status Epilepticus/physiopathology , Thalamus/physiopathology , Adolescent , Child , Child, Preschool , Electroencephalography , Female , Humans , Male , Sleep Wake Disorders/physiopathologyABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Withania somnifera (Family: Solanaceae), commonly known as Ashwagandha or Indian ginseng is distributed widely in India, Nepal, China and Yemen. The roots of plant consist of active phytoconstituents mainly withanolides, alkaloids and sitoindosides and are conventionally used for the treatment of multiple brain disorders. AIM OF THE REVIEW: This review aims to critically assess and summarize the current state and implication of Ashwagandha in brain disorders. We have mainly focussed on the reported neuroactive phytoconstituents, available marketed products, pharmacological studies, mechanism of action and recent patents published related to neuroprotective effects of Ashwagandha in brain disorders. MATERIALS AND METHODS: All the information and data was collected on Ashwagandha using keywords "Ashwagandha" along with "Phytoconstituents", "Ayurvedic, Unani and Homeopathy marketed formulation", "Brain disorders", "Mechanism" and "Patents". Following sources were searched for data collection: electronic scientific databases such as Science Direct, Google Scholar, Elsevier, PubMed, Wiley On-line Library, Taylor and Francis, Springer; books such as AYUSH Pharmacopoeia; authentic textbooks and formularies. RESULTS: Identified neuroprotective phytoconstituents of Ashwagandha are sitoindosides VII-X, withaferin A, withanosides IV, withanols, withanolide A, withanolide B, anaferine, beta-sitosterol, withanolide D with key pharmacological effects in brain disorders mainly anxiety, Alzheimer's, Parkinson's, Schizophrenia, Huntington's disease, dyslexia, depression, autism, addiction, amyotrophic lateral sclerosis, attention deficit hyperactivity disorder and bipolar disorders. The literature survey does not highlight any toxic effects of Ashwagandha. Further, multiple available marketed products and patents recognized its beneficial role in various brain disorders; however, very few data is available on mechanistic pathway and clinical studies of Ashwagandha for various brain disorders is scarce and not promising. CONCLUSION: The review concludes the results of recent studies on Ashwagandha suggesting its extensive potential as neuroprotective in various brain disorders as supported by preclinical studies, clinical trials and published patents. However vague understanding of the mechanistic pathways involved in imparting the neuroprotective effect of Ashwagandha warrants further study to promote it as a promising drug candidate.
Subject(s)
Brain Diseases/drug therapy , Brain/drug effects , Neuroprotective Agents/therapeutic use , Phytotherapy , Plant Extracts/therapeutic use , Animals , Brain/metabolism , Brain/pathology , Brain/physiopathology , Brain Diseases/metabolism , Brain Diseases/pathology , Brain Diseases/physiopathology , Drug Development/legislation & jurisprudence , Drug Discovery/legislation & jurisprudence , Humans , Neuroprotective Agents/adverse effects , Neuroprotective Agents/isolation & purification , Patents as Topic , Plant Extracts/adverse effects , Plant Extracts/chemistry , Plant Extracts/isolation & purification , Plant Roots , Signal TransductionABSTRACT
Chronic-diabetes-related complications simultaneously compromise both the micro- and macrovascular trees, with target organs considered as the paradigm of large vessel injury also entailing microangiopathic changes. However, complications independent or partially independent from vascular damage are often overlooked. This includes neuronal dysfunction (e.g., retinal neurodegeneration), interstitial injury (e.g., tubulointerstitial disease), metabolic damage (e.g., in the heart and liver), and nonclassical conditions such as cognitive decline, impaired pulmonary function, or increased risk of cancer. In this scenario, researchers, endocrinologists and primary care physicians should have a holistic view of the disease and pay further attention to all organs and all potential clinical repercussions, which would certainly contribute to a more rational and integrated patient health care.
Subject(s)
Brain Diseases , Diabetes Complications , Diabetic Angiopathies , Diabetic Cardiomyopathies , Diabetic Nephropathies , Diabetic Neuropathies , Lung Diseases , Neoplasms , Non-alcoholic Fatty Liver Disease , Brain Diseases/etiology , Brain Diseases/pathology , Brain Diseases/physiopathology , Diabetes Complications/complications , Diabetes Complications/pathology , Diabetic Angiopathies/etiology , Diabetic Angiopathies/pathology , Diabetic Angiopathies/physiopathology , Diabetic Cardiomyopathies/etiology , Diabetic Cardiomyopathies/pathology , Diabetic Cardiomyopathies/physiopathology , Diabetic Nephropathies/etiology , Diabetic Nephropathies/pathology , Diabetic Nephropathies/physiopathology , Diabetic Neuropathies/etiology , Diabetic Neuropathies/pathology , Diabetic Neuropathies/physiopathology , Humans , Lung Diseases/etiology , Lung Diseases/pathology , Lung Diseases/physiopathology , Neoplasms/etiology , Neoplasms/pathology , Neoplasms/physiopathology , Non-alcoholic Fatty Liver Disease/etiology , Non-alcoholic Fatty Liver Disease/pathology , Non-alcoholic Fatty Liver Disease/physiopathologyABSTRACT
BACKGROUND: Wernicke-Korsakoff Syndrome (WKS) resulting from thiamine deficiency is classically defined as including encephalopathy, ataxia, and ophthalmoplegia. Only 16% of autopsy-confirmed patients with WKS exhibit all three signs. Caine-positive WKS criteria include two or more of the following: nutritional deficiency, delirium or mild memory impairment, cerebellar dysfunction/ataxia, and oculomotor abnormalities. OBJECTIVE: We describe Caine-positive WKS prevalence among psychiatric inpatients and compare pretreatment-versus-posttreatment neurocognitive improvement to an unaffected group. METHODS: This 6-month quality-improvement evaluation included two-stage screening for Caine-positive WKS, administering high-dose intravenous thiamine (day 1: 1200 mg; days 2-4: 200 mg) with reexamination on day 5. We used descriptive statistics and fitted random effects models to examine rate-of-change differences in pre-/posttreatment Montreal Cognitive Assessment (MoCA), delayed 5-item recall, and gait/coordination scores between treated Caine-positive patients with WKS and untreated Caine-negative patients. RESULTS: Of 262 patients, 32 (12%) had Caine-positive WKS; 17 (53%) used alcohol currently. Treated Caine-positive WKS (n = 26) versus Caine-negative comparison (n = 34) before and after treatment observed a mean change (standard deviation) in the MoCA score of 3.6 (2.5) versus 1.8 (2.5) (P < 0.01); 5-item recall: 1.8 (1.4) versus 0.5 (1.4) (P < 0.001); gait/coordination scores: -0.6 (1.2) versus -0.1 (0.6) (P < 0.001). Oculomotor abnormalities were infrequent (n = 4 in Caine-positive WKS, n = 2 in Caine-negative comparison groups). CONCLUSIONS: Caine-positive WKS prevalence among psychiatric inpatients was 12%; only half used alcohol. Patients treated with high-dose thiamine demonstrated clinically significant neurocognitive improvement.
Subject(s)
Ataxia/physiopathology , Brain Diseases/physiopathology , Korsakoff Syndrome/epidemiology , Ophthalmoplegia/physiopathology , Adult , Alcoholic Korsakoff Syndrome/diagnosis , Alcoholic Korsakoff Syndrome/drug therapy , Alcoholic Korsakoff Syndrome/epidemiology , Alcoholic Korsakoff Syndrome/physiopathology , Cerebellar Diseases/physiopathology , Delirium/physiopathology , Female , Hospitalization , Humans , Korsakoff Syndrome/diagnosis , Korsakoff Syndrome/drug therapy , Korsakoff Syndrome/physiopathology , Male , Malnutrition/epidemiology , Mass Screening , Memory Disorders/physiopathology , Mental Status and Dementia Tests , Middle Aged , Ocular Motility Disorders/physiopathology , Prevalence , Thiamine/therapeutic use , Thiamine Deficiency/drug therapy , Thiamine Deficiency/physiopathology , Thinness/epidemiology , Treatment Outcome , Vitamin B Complex/therapeutic use , Weight LossSubject(s)
Brain Diseases/diagnosis , Carbon Monoxide Poisoning/diagnosis , Kidney Transplantation , Aged , Brain Diseases/physiopathology , Brain Diseases/therapy , Carbon Monoxide Poisoning/physiopathology , Carbon Monoxide Poisoning/therapy , Delayed Diagnosis , Diagnosis, Differential , Humans , Hyperbaric Oxygenation , Immunosuppressive Agents/administration & dosage , Male , Predictive Value of Tests , Recovery of Function , Time Factors , Treatment OutcomeABSTRACT
Thiamine metabolism dysfunction syndrome-4 (THMD4) includes episodic encephalopathy, often associated with a febrile illness, causing transient neurologic dysfunction and a slowly progressive axonal polyneuropathy. Until now only two mutations (G125S and S194P) have been reported in the SLC25A19 gene as causative for this disease and a third mutation (G177A) as related to the Amish lethal microcephaly. In this work, we describe the clinical and molecular features of a patient carrying a novel mutation (c.576G>C; Q192H) on SLC25A19 gene. Functional studies on this mutation were performed explaining the pathogenetic role of c.576G>C in affecting the translational efficiency and/or stability of hMTPPT protein instead of the mRNA expression. These findings support the pathogenetic role of Q192H (c.576G>C) mutation on SLC25A19 gene. Moreover, despite in other patients the thiamine supplementation leaded to a substantial improvement of peripheral neuropathy, our patient did not show a clinical improvement.
Subject(s)
Genetic Predisposition to Disease , Microcephaly/genetics , Mitochondrial Membrane Transport Proteins/genetics , Thiamine Deficiency/genetics , Adolescent , Brain Diseases/genetics , Brain Diseases/physiopathology , Humans , Male , Microcephaly/physiopathology , Mitochondrial Membrane Transport Proteins/chemistry , Mutation , Protein Conformation , RNA, Messenger/genetics , Thiamine/genetics , Thiamine/metabolism , Thiamine Deficiency/physiopathologyABSTRACT
EEG activation of interictal epileptiform discharges (IEDs) during NREM sleep is a well-described phenomenon that occurs in the majority of epileptic syndromes. In drug-resistant focal epilepsy, IED activation seems to be related to slow wave activity (SWA), especially during arousal fluctuations, namely phase A of the cyclic alternating pattern (CAP). Conversely, in childhood focal epileptic syndromes, including Encephalopathy related to Status Epilepticus during slow Sleep (ESES), IED activation seems primarily modulated by sleep-inducing and maintaining mechanisms as reflected by the dynamics of spindle frequency activity (SFA) rather than SWA. In this article, we will review the effect of sleep on IEDs with a particular attention on the activation and modulation of IEDs in ESES. Finally, we will discuss the role of the thalamus and cortico-thalamic circuitry in this syndrome.
Subject(s)
Brain Diseases/physiopathology , Sleep/physiology , Status Epilepticus/physiopathology , Thalamus/physiopathology , Brain Diseases/diagnosis , Child , Electroencephalography/methods , Epilepsies, Partial/physiopathology , Humans , Status Epilepticus/diagnosisABSTRACT
Neurological, neurodegenerative, and psychiatric disorders represent a serious burden because of their increasing prevalence, risk of disability, and the lack of effective causal/disease-modifying treatments. There is a growing body of evidence indicating potentially favourable effects of carnosine, which is an over-the-counter food supplement, in peripheral tissues. Although most studies to date have focused on the role of carnosine in metabolic and cardiovascular disorders, the physiological presence of this di-peptide and its analogues in the brain together with their ability to cross the blood-brain barrier as well as evidence from in vitro, animal, and human studies suggest carnosine as a promising therapeutic target in brain disorders. In this review, we aim to provide a comprehensive overview of the role of carnosine in neurological, neurodevelopmental, neurodegenerative, and psychiatric disorders, summarizing current evidence from cell, animal, and human cross-sectional, longitudinal studies, and randomized controlled trials.
Subject(s)
Brain Diseases/drug therapy , Brain/drug effects , Carnosine/therapeutic use , Cognition/drug effects , Dietary Supplements , Neuroprotective Agents/therapeutic use , Animals , Brain/metabolism , Brain/pathology , Brain/physiopathology , Brain Diseases/metabolism , Brain Diseases/physiopathology , Brain Diseases/psychology , Carnosine/adverse effects , Dietary Supplements/adverse effects , Humans , Neuroprotective Agents/adverse effectsABSTRACT
Unhealthy diet promotes progression of metabolic disorders and brain dysfunction with aging. Green tea extracts (GTEs) have various beneficial effects and alleviate metabolic disorders. GTEs have neuroprotective effects in rodent models, but their effects against brain dysfunction in models of aging fed unhealthy diets are still unclear. Here, we showed that GTEs attenuate high-fat (HF) diet-induced brain dysfunction in senescence-accelerated mouse prone-8 (SAMP8), a murine model of senescence. SAMP8 mice were fed a control diet, HF diet, or HF diet with 0.5% GTEs (HFGT) for four months. The HF diet reduced memory retention and induced amyloid ß1-42 accumulation, whereas GTEs attenuated these changes. In HF diet-fed mice, lipid oxidative stress, assessed by malondialdehyde levels, was increased. The levels of proteins that promote synaptic plasticity, such as brain-derived neurotrophic factor (BDNF) and postsynaptic density protein 95 (PSD95), were reduced. These alterations related to brain dysfunction were not observed in HFGT diet-fed mice. Overall, our data suggest that GTEs intake might attenuate brain dysfunction in HF diet-fed SAMP8 mice by protecting synaptic plasticity as well as via anti-oxidative effects. In conclusion, GTEs might ameliorate unhealthy diet-induced brain dysfunction that develops with aging.
Subject(s)
Brain Diseases/drug therapy , Diet, High-Fat/adverse effects , Neuroprotective Agents , Plant Extracts/administration & dosage , Tea , Aging , Amyloid beta-Peptides/analysis , Animals , Brain/pathology , Brain Chemistry , Brain Diseases/etiology , Brain Diseases/physiopathology , Brain-Derived Neurotrophic Factor/analysis , Cognitive Dysfunction/drug therapy , Cognitive Dysfunction/etiology , Disks Large Homolog 4 Protein/analysis , Male , Memory , Mice , Neuronal Plasticity , Organ Size , Oxidative Stress/drug effects , Phytotherapy , Synaptophysin/analysisABSTRACT
To elucidate location and characteristics of the central thermoregulatory sudomotor pathway in the human brainstem, thermoregulatory sweating (TS) in 91 patients with focal brainstem lesions was studied. TS was symmetric or minimally asymmetric in 40 subjects (Group S), and was apparently asymmetric in 51 patients (Group AS). In Group AS, the main abnormality was ipsilateral segmental hypohidrosis with a varying extent, involving predominantly the upper half of the body. Lesion locations, correlations between thermoregulatory sweat test results, and other autonomic and somatic functions were compared between the groups. The results suggested following: (1) The hypothalamospinal pathway related to TS may pass through the posterior hypothalamus and descend in the dorsolateral part of the brainstem, near the spinal trigeminal and spinothalamic tracts; (2) the pathway may descend together with those related to oculosympathetic and vasoconstrictor systems, but each of these may form distinct fiber groups; (3) the majority of the central TS fibers may reach ipsilateral sudomotor sympathetic neurons of the spinal cord, even though some fibers may cross at various levels; (4) in this descending pathway, somatotopic arrangements corresponding to each of the spinal sympathetic segments must be present; (5) There may be another fiber group passing through the central to dorsal paramedian portions of the brainstem, and lesions of these fibers also result in asymmetric TS, but seldom in oculosympathetic dysfunction. This second pathway probably exerts contralateral inhibitory influence on TS, but its origin, intracerebral course and exact physiological function require further clinical investigations.
Subject(s)
Brain Stem/physiology , Hypothalamus/physiology , Neural Pathways/anatomy & histology , Neural Pathways/physiology , Sweat Glands/physiology , Sweating/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Brain Diseases/pathology , Brain Diseases/physiopathology , Brain Stem/pathology , Brain Stem/physiopathology , Female , Humans , Male , Middle Aged , Young AdultABSTRACT
Thiamine pyrophosphokinase (TPK) converts thiamine (vitamin B1) into thiamine pyrophosphate (TPP), an essential cofactor for many important enzymes. TPK1 mutations lead to a rare disorder: episodic encephalopathy type thiamine metabolism dysfunction. Yet, the molecular mechanism of the disease is not entirely clear. Here we report an individual case of episodic encephalopathy, with familial history carrying a novel homozygous TPK1 mutation (p.L28S). The L28S mutation leads to reduced enzymatic activity, both in vitro and in vivo, without impairing thiamine binding and protein stability. Thiamine supplementation averted encephalopathic episodes and restored the patient's developmental progression. Biochemical characterization of reported TPK1 missense mutations suggested reduced thiamine binding as a new disease mechanism. Importantly, many disease mutants are directly or indirectly involved in thiamine binding. Thus, our study provided a novel rationale for thiamine supplementation, so far the major therapeutic intervention in TPK deficiency.
Subject(s)
Brain Diseases/genetics , Thiamin Pyrophosphokinase/deficiency , Thiamin Pyrophosphokinase/genetics , Thiamine/genetics , Amino Acid Sequence/genetics , Brain Diseases/physiopathology , Child, Preschool , China , Female , Homozygote , Humans , Male , Mutation, Missense/genetics , Pedigree , Protein Binding , Protein Stability , Thiamin Pyrophosphokinase/chemistry , Thiamine/metabolism , Thiamine Pyrophosphate/genetics , Thiamine Pyrophosphate/metabolismABSTRACT
BACKGROUND: Incidence and patterns of brain lesions of sepsis-induced brain dysfunction (SIBD) have been well defined. Our objective was to investigate the associations between neuroimaging features of SIBD patients and well-known neuroinflammation and neurodegeneration factors. METHODS: In this prospective observational study, 93 SIBD patients (45 men, 48 women; 50.6 ± 12.7 years old) were enrolled. Patients underwent a neurological examination and brain magnetic resonance imaging (MRI). Severity-of-disease scoring systems (APACHE II, SOFA, and SAPS II) and neurological outcome scoring system (GOSE) were used. Also, serum levels of a panel of mediators [IL-1ß, IL-6, IL-8, IL-10, IL-12, IL-17, IFN-γ, TNF-α, complement factor Bb, C4d, C5a, iC3b, amyloid-ß peptides, total tau, phosphorylated tau (p-tau), S100b, neuron-specific enolase] were measured by ELISA. Voxel-based morphometry (VBM) was employed to available patients for assessment of neuronal loss pattern in SIBD. RESULTS: MRI of SIBD patients were normal (n = 27, 29%) or showed brain lesions (n = 51, 54.9%) or brain atrophy (n = 15, 16.1%). VBM analysis showed neuronal loss in the insula, cingulate cortex, frontal lobe, precuneus, and thalamus. Patients with abnormal MRI findings had worse APACHE II, SOFA, GOSE scores, increased prevalence of delirium and mortality. Presence of MRI lesions was associated with reduced C5a and iC3b levels and brain atrophy was associated with increased p-tau levels. Regression analysis identified an association between C5a levels and presence of lesion on MRI and p-tau levels and the presence of atrophy on MRI. CONCLUSIONS: Neuronal loss predominantly occurs in limbic and visceral pain perception regions of SIBD patients. Complement breakdown products and p-tau stand out as adverse neuroimaging outcome markers for SIBD.
Subject(s)
Brain Diseases , Cerebral Cortex/pathology , Sepsis/complications , Thalamus/pathology , Adult , Brain Diseases/blood , Brain Diseases/etiology , Brain Diseases/pathology , Brain Diseases/physiopathology , Cerebral Cortex/diagnostic imaging , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Prospective Studies , Severity of Illness Index , Thalamus/diagnostic imagingABSTRACT
RATIONALE AND OBJECTIVES: As a special movement disorder, hepatic myelopathy (HM) is characterized by spastic paraperesis and may be secondary to transjugular intrahepatic portosystemic shunt (TIPS). The prediction and diagnosis of HM is difficult due to largely unknown neuropathological underpinnings and a lack of specific biomarkers. We aimed to delve into the alterations in motor system of HM patients' brain and their potential clinical implication. MATERIAL AND METHODS: Twenty-three patients with HM and 23 without HM after TIPS and 24 demographically matched healthy controls were enrolled. High-spatial-resolution structural imaging and functional data at rest were acquired. Motor areas were included as seed regions for functional connectivity analysis. Then, we performed brain volume analysis. RESULTS: We found decreased right supplementary motor area (SMA)-seeded functional connectivity with bilateral insula, thalamus and midbrain, left cerebellum and middle temporal gyrus, and right middle cingulate gyrus in HM compared to non-HM patients (p < 0.001). The right insula revealed decreased volume (p < 0.001), and white matter volume reduced in the right corona radiata beneath the right SMA (p < 0.001) in HM relative to non-HM patients. Furthermore, the strength of right SMA-seeded connectivity with insula was positively correlated with folic acid level in HM patients (râ¯=â¯0.60, p = 0.03), showing an accuracy of 0.87 to distinguish HM from non-HM. CONCLUSION: Our study demonstrates the HM-specific dysconnectivity with an anatomical basis, and its correlation with laboratory findings and diagnostic value. Detecting these abnormalities might help to predict and diagnose post-TIPS HM.
Subject(s)
Brain Diseases/pathology , Motor Cortex/pathology , Portasystemic Shunt, Transjugular Intrahepatic , Spinal Cord Diseases/pathology , Biomarkers/metabolism , Brain/pathology , Brain/physiopathology , Brain Diseases/physiopathology , Brain Mapping/methods , Case-Control Studies , Female , Humans , Liver Cirrhosis/pathology , Liver Cirrhosis/physiopathology , Male , Middle Aged , Motor Cortex/physiopathology , Organ Size/physiology , Paraparesis, Spastic/pathology , Paraparesis, Spastic/physiopathology , Postoperative Complications/pathology , Postoperative Complications/physiopathology , Spinal Cord Diseases/physiopathology , White Matter/pathology , White Matter/physiopathologyABSTRACT
Many Brain Computer Interface (BCI) and neurofeedback studies have investigated the impact of sensorimotor rhythm (SMR) self-regulation training procedures on motor skills enhancement in healthy subjects and patients with motor disabilities. This critical review aims first to introduce the different definitions of SMR EEG target in BCI/Neurofeedback studies and to summarize the background from neurophysiological and neuroplasticity studies that led to SMR being considered as reliable and valid EEG targets to improve motor skills through BCI/neurofeedback procedures. The second objective of this review is to introduce the main findings regarding SMR BCI/neurofeedback in healthy subjects. Third, the main findings regarding BCI/neurofeedback efficiency in patients with hypokinetic activities (in particular, motor deficit following stroke) as well as in patients with hyperkinetic activities (in particular, Attention Deficit Hyperactivity Disorder, ADHD) will be introduced. Due to a range of limitations, a clear association between SMR BCI/neurofeedback training and enhanced motor skills has yet to be established. However, SMR BCI/neurofeedback appears promising, and highlights many important challenges for clinical neurophysiology with regards to therapeutic approaches using BCI/neurofeedback.
Subject(s)
Brain Waves , Brain-Computer Interfaces , Motor Skills , Neurofeedback/methods , Sensorimotor Cortex/physiology , Animals , Brain Diseases/physiopathology , Brain Diseases/rehabilitation , Humans , Imagination , Mental Disorders/physiopathology , Mental Disorders/rehabilitation , Models, Neurological , Neurofeedback/instrumentation , Neuronal Plasticity , Sensorimotor Cortex/physiopathologyABSTRACT
Non-invasive stimulation of the cerebellum is growingly applied both in the clinic and in research settings to modulate the activities of cerebello-cerebral loops. The anatomical location of the cerebellum, the high responsiveness of the cerebellar cortex to magnetic/electrical stimuli, and the implication of the cerebellum in numerous cerebello-cerebral networks make the cerebellum an ideal target for investigations and therapeutic purposes. In this mini-review, we discuss the potentials of cerebellar neuromodulation in major brain disorders in order to encourage large-scale sham-controlled research and explore this therapeutic aid further.
Subject(s)
Brain Diseases/therapy , Cerebellar Cortex , Electric Stimulation Therapy , Mental Disorders/therapy , Movement Disorders/therapy , Animals , Brain Diseases/physiopathology , Cerebellar Cortex/physiopathology , Humans , Mental Disorders/physiopathology , Movement Disorders/physiopathologyABSTRACT
OBJECTIVE: To compare use of standard enteral formula versus enteric formula with prebiotic content in terms of nutrition therapy related outcomes among neurocritical care patients. METHODS: A total of 46 adult neurocritical care patients who received nutrition therapy with standard enteral formula (SEF group; n = 23) or enteral formula with prebiotic content (EFPC group; n = 23) during their hospitalization in intensive care unit (ICU) were included in this prospective randomized controlled study. Data on patient demographics (age, gender), diagnosis, co-morbid diseases, anthropometrics, length of stay (LOS) in hospital and ICU, Nutritional Risk Screening (NRS-2002) score, and Acute Physiology and Chronic Health (APACHE-II) score were recorded at enrollment. Data on daily nutritional intake [total energy (kcal/day), carbohydrate (g/day), protein (g/day), lipid (g/day), FOS (g/day), enteral volume (ml/day), fluid in enteral product (ml/day) and fluid intake (ml/day)], achievement of target dose [total fluid intake in enteral product (ml)/20 h], laboratory findings (blood biochemistry and complete blood count), complications and drug treatments were recorded on Day 1, Day 4, Day 7, Day 14 and Day 21 of nutrition therapy in SEF and EFPC groups. RESULTS: Use of EFPC compared to SEF was associated with significantly higher total energy, carbohydrate, protein, lipid, enteral volume and fluid intake (p values ranged from <0.05 to <0.001) on each day of nutrition therapy. Target dose was achieved by majority of patients (86.9%) and at day 4 of nutrition therapy in most of patients (71.7%) in the overall study population. Patients in the EFPC group had a non-significant tendency for higher rate (95.7% vs. 78.3%) and earlier (87.0% vs. 56.5% on day 4) achievement of target dose, lower rate (8.7% vs. 56.5%) and faster amelioration (none vs. 52.2% were diarrheic on day 7) of diarrhea and lesser need for insulin (56.5% vs. 13.0%, p = 0.002). Nutrition therapy was associated with significant decrease in prealbumin (Day 14 vs. Day 1, p < 0.05 for both), albumin (Day 14 vs. day 1, p < 0.01 for SEF, p < 0.05 for PEF), hemoglobin (Day 14 and Day 21 vs. Day 1and Day 14 vs. Day 4, p < 0.001 for each for SEF, Day 7, Day 14 and Day 21 vs. Day 1, p < 0.01 for each for PEF) and hematocrit (Day 14 and Day 21 vs. Day 1, p < 0.001 for each for both) levels in both SEF and EFPC groups. CONCLUSIONS: In conclusion, our findings revealed achievement of target nutritional intake in majority of neurocritical care patients via nutrition therapy, whereas EFPC was associated with a non-significant tendency for more frequent and earlier achievement of target dose along with significantly lower rate and faster amelioration of diarrhea as compared with SEF group. Prealbumin and albumin levels remained below the normal range, whereas C reactive protein (CRP) and white blood cell (WBC) were over the normal range throughout the nutrition period in both groups, while creatinine and urea levels were higher in EFPC than in SEF group. Hence, our findings seem to emphasize the importance of avoiding protein debt in provision of nutrition therapy and the likelihood of deterioration of nutritional status in elderly neurocritical care patients despite provision of early enteral nutrition support due to complex and deleterious inflammatory and metabolic changes during critical illness.